Jpmorgan Chase & CO Vir Biotechnology, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VIR
# of Institutions
224Shares Held
87.5MCall Options Held
231KPut Options Held
132K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$156 Million1.37% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$154 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$120 Million0.0% of portfolio
-
State Street Corp Boston, MA5.09MShares$47.7 Million0.0% of portfolio
-
Baillie Gifford & CO2.38MShares$22.3 Million0.01% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.24B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...